Esperion Therapeutics (ESPR) Enterprise Value (2012 - 2026)

Esperion Therapeutics has reported Enterprise Value for 15 years, with the latest figure at -$156.2 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 36.22% year-over-year to -$156.2 million; the trailing twelve-month figure through Mar 2026 stood at -$156.2 million (down 36.22% YoY), and the FY2025 full-year result was -$167.9 million, down 15.95% from the prior year.
• Enterprise Value for Q1 2026 stood at -$156.2 million, up from -$167.9 million in the prior quarter.
• The five-year high for Enterprise Value was -$82.2 million in Q4 2023, with the low at -$226.6 million in Q1 2024.
• Historically, Enterprise Value has averaged -$151.8 million across 5 years, with a median of -$156.2 million in 2026.
• Annual changes were most pronounced in 2022 — Enterprise Value sank 82.63% — and 2025, when it soared 54.54%.
• Esperion Therapeutics' Enterprise Value stood at -$166.9 million in 2022, then jumped by 50.71% to -$82.2 million in 2023, then sank by 76.01% to -$144.8 million in 2024, then decreased by 15.95% to -$167.9 million in 2025, then advanced by 6.97% to -$156.2 million in 2026.
• The last three Enterprise Value figures came in at -$156.2 million (Q1 2026), -$167.9 million (Q4 2025), and -$92.4 million (Q3 2025), per Business Quant data.